1724 results for Treatments
Refine Your Search
FDA Approves New Treatment for Children and Young Adults with Chronic Graft versus Host Disease
This week marked another milestone for the treatment of graft versus host disease in children. The U.S. Food and Drug Administration (FDA) approved ib…
News Release
FDA Approves New Targeted Treatment Option for Certain Forms of Acute Myeloid Leukemia in Adults
The U.S. Food and Drug Administration (FDA) granted approval yesterday to olutasidenib (Rezlidhia™) for the treatment of adults with acute myeloid leu…
News Release
FDA Approves New Treatment Option For Chronic Graft-Versus-Host-Disease In Patients Ages 12 Years And Older
RYE BROOK, N.Y., August , - The U.S. Food and Drug Administration (FDA) recently approved belumosudil (Rezurock™) in patients years or older for the…
News Release
BRAF inhibition as an alternative to chemotherapy in the treatment strategy of hairy cell leukemia
Hairy cell leukemia (HCL) is very sensitive to chemotherapy, whose toxicity to the bone marrow and the immune system is however concerning. We have es…
FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse
The U.S. Food and Drug Administration (FDA) recently granted the seventh approval to daratumumab for the treatment of multiple myeloma. This injectabl…
News Release
FDA Approval of New CAR T-Cell Therapy Further Solidifies Immunotherapy as a Mainstay in Cancer Treatment
The U.S. Food and Drug Administration (FDA) today announced approval of a new CAR treatment for adult patients with certain forms of relapsed/refract…
News Release
Another First: FDA Approves Car T-Immunotherapy for Treatment of Aggressive Form of Indolent Non-Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) today approved the CAR treatment axicabtagene ciloleucel (Yescarta®) for patients with follicular lymphom…
X4 Pharmaceuticals Announces FDA Fast Track Designation Granted to Mavorixafor for the Treatment of WHIM Syndrome
BOSTON, Oct. , - X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting f…
News Release
The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs
Numerous researchers and Therapy Acceleration Program (TAP) partners will present data on the most recent developments in blood cancer.LLS’s scientif…
News Release
BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Cutaneous T-cell Lymphoma
LUND, SWEDEN, April , – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development…
News Release
Sutro Biopharma Presents Data for STRO-001 for the Treatment of NHL and AML at ASH
SOUTH SAN FRANCISCO, Calif., Dec. , – Sutro Biopharma, Inc. (NASDAQ: STRO), a drug discovery, development and manufacturing company focused on the a…
IMPACT CLL & MCL: IMPlementing Advances in Cancer Treatment for Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
This educational activity is intended for an audience of hematologists/oncologists, members of the oncology multidisciplinary team (MDT; nurses, nurse…
The Leukemia & Lymphoma Society (LLS) Data at ASH Provides Glimpse into the Future of Blood Cancer Treatment
New data from LLS master clinical trials — Beat AML® and Pediatric Acute Leukemia (PedAL) — show promise for leukemias Leaders available to provide …
News Release
FDA OKs the First All-Oral, Time‑Limited Treatment Option for Adults Newly Diagnosed with Most Common Form of Leukemia
A major focus of Blood Cancer United's work is supporting time‑limited treatments like this new acalabrutinib approval that are effective but do not r…
News Release
Kymera Therapeutics Receives IND Clearance for KT-333, a STAT3 Degrader, for the Treatment of Hematologic and Solid Malignancies
WATERTOWN, Mass., Nov. , - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver n…
More treatments for more patients and the growing impact of AI on health: A report from recent medical conferences
Dr. Lore Gruenbaum breaks down the biggest takeaways from ASCO and EHA.
Blog
Treatment
Stratified treatment of newly diagnosed MCL based on the presence or absence of high risk features utilizing non-cytotoxic agents.
We believe that regimens without chemotherapy can induce significant and durable remissions in patients with Mantle cell lymphoma (MCL). We will confi…
Immune-Onc Therapeutics Announces IO-202 Granted Fast Track Designation by FDA for the Treatment of Relapsed or Refractory CMML
PALO ALTO, Calif., June , – Therapeutics, Inc. (“”), a private, oncology company dedicated to the discovery and development of novel biotherapeutic…
News Release
Suggested Reading - Coping with the Emotional Impact of Cancer: Become an Active Patient and Take Charge of Your Treatment
The author of this book is a -year survivor of a terminal cancer diagnosis, dramatically demonstrates how patients can maintain personal control of th…
Secura Bio Announces the Presentation of New COPIKTRA® (duvelisib) Data for the Treatment of Patients with Relapsed or Refractory PTCL
SUMMERLIN, Nev., Dec. , - Secura Bio, Inc., an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impa…
Valvoline™ Global Operations Announces Major Commitment to The Leukemia & Lymphoma Society to Power Better Treatments for Kids with Blood Cancer Worldwide
LEXINGTON, KY & RYE BROOK, NY, SEPTEMBER , – Valvoline Global Operations, a worldwide leader in automotive and industrial solutions creating product…
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)
SANTA MONICA, Calif. April , - Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescar…
News Release
Suggested Reading - Having Children After Cancer:How to Make Informed Choices before and After Treatment and Build the Family of Your Dreams
When faced with a cancer diagnosis, many doctors and patients rush ahead into treatment, giving minimal attention to the potential fertility implicat…
BioInvent announces promising initial efficacy data from triple combination arm of BI-1206, rituximab and Calquence for the treatment of non-Hodgkin's lymphoma
Lund, Sweden – January , – BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and developm…
Education Resources